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Abstract
Aspirin-intolerant asthma (AIA) is a rare condition that is characterized by the development of bronchoconstriction in
asthmatic patients after ingestion of non-steroidal anti-inflammatory drugs including aspirin. However, the underlying
mechanisms of AIA occurrence are still not fully understood. To identify the genetic variations associated with aspirin
intolerance in asthmatics, the first stage of genome-wide association study with 109,365 single nucleotide polymorphisms
(SNPs) was undertaken in a Korean AIA (n=80) cohort and aspirin-tolerant asthma (ATA, n=100) subjects as controls. For
the second stage of follow-up study, 150 common SNPs from 11 candidate genes were genotyped in 163 AIA patients
including intermediate AIA (AIA-I) subjects and 429 ATA controls. Among 11 candidate genes, multivariate logistic analyses
showed that SNPs of CEP68 gene showed the most significant association with aspirin intolerance (P values of co-dominant
for CEP68, 6.0610
25 to 4.0610
25). All seven SNPs of the CEP68 gene showed linkage disequilibrium (LD), and the haplotype
of CEP68_ht4 (T-G-A-A-A-C-G) showed a highly significant association with aspirin intolerance (OR =2.63; 95% CI =1.64–
4.21; P=6.0610
25). Moreover, the nonsynonymous CEP68 rs7572857G.A variant that replaces glycine with serine showed a
higher decline of forced expiratory volume in 1s (FEV1) by aspirin provocation than other variants (P=3.0610
25). Our
findings imply that CEP68 could be a susceptible gene for aspirin intolerance in asthmatics, suggesting that the
nonsynonymous Gly74Ser could affect the polarity of the protein structure.
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Introduction
Aspirin, also known as acetylsalicylic acid, has been used as an
analgesic to relieve pain and fever, as well as an anti-inflammatory
medication. Up to 20% of asthmatics are sensitive to aspirin and
other non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin-
intolerant asthma (AIA), as a unique clinical syndrome with acute
bronchospasm after ingestion of aspirin or other NSAIDs, was first
described in 1922 [1,2]. AIA is characterized by the triad of
aspirin hypersensitivity, bronchial asthma, and chronic rhinosinu-
sitis with nasal polyposis [3,4]. AIA progression from the upper to
the lower respiratory tract is accompanied by persistent asthmatic
symptoms with intense eosinophilic infiltration into the upper and
lower airways. AIA generally begins at about 30 years of age and
occurs more frequently in women [2,5].
Recent studies have shown that aspirin hypersensitivity is
likely to be related with over-production of pro-inflammatory
cysteinyl leukotrienes (CysLTs) such as LTC4, LTD4, and
LTE4 [2]. CysLTs are generated from arachidonic acid via the
leukotriene synthetic pathway or the 5-lipoxygenase pathway.
Aspirin blocks the cyclooxygenase pathway that converts
arachidonic acid into prostaglandins, and eventually diverts
arachidonic acid metabolites to the 5-lipoxygenase pathway
[6,7]. Therefore, CysLT receptors and arachidonic acid
cascade-related enzymes/proteins have been considered as
main targets for aspirin intolerance in asthmatics. CysLT
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modifiers, such as montelukast, pranlukast, and zafirlukast [8,9];
however, clinical studies have demonstrated that the responses
to these drugs is incomplete [10,11], suggesting the presence of
an alternative pathway leading to AIA. Previous genetic studies
have revealed significant associations between AIA and the
polymorphisms of cysteinyl leukotriene receptor 1 [12], cysteinyl
leukotriene receptor 2 [13], thromboxane A2 receptor [14], and
prostaglandin E2 receptor subtype 2 [15]. The genetic
polymorphisms of leukotriene C4 synthase (LTC4S) [16,17,18]
and arachidonate 5-lipoxygenase (ALOX5) [19,20] have been
reported to be positively or negatively associated with AIA
depending on populations and polymorphic loci. In addition to
the genes on the arachidonate pathway, genetic variants on TNF
[21], HLA [22,23,24], TBX21 [25], ACE [26], IL-10/TGF [27],
and NLRP3 [28] genes in the pathways of immune response and
inflammation are also associated with aspirin hypersensitivity in
asthmatics. These data suggest that genetic variants of genes on
other pathways may be more relevant to development of aspirin
hypersensitivity in asthmatics than was previously thought.
Genome-wide association studies (GWAS) have recently
emerged as a technology in predicting genetic variations across
the genome that are associated with human diseases and clinical
response to drug treatment [29,30]. Recently, GWAS for
asthma and related phenotypes have reported several suscepti-
ble genes including ORMDL3, PDE4D and IL1RL1 [31,32,33].
In the case of AIA, most of the recent genetic association
analyses have been investigated through candidate gene
approaches. Therefore, genome-wide association analysis and
follow-up study of aspirin intolerance in asthmatics were
performed in order to identify novel and comprehensive
etiology of AIA.
Results
Characteristics of the Study Subjects
The clinical characteristics and comparisons of AIA, interme-
diate AIA (AIA-I), and ATA groups are summarized in Table 1.
First of all, an aspirin-induced decline in FEV1 of 215% to 68%
was observed in all study subjects. In both of genome-wide and
follow-up studies, the % declines of FEV1 by aspirin provocation
in AIA and AIA-I patients were significantly increased compared
to those of ATA controls (P,0.0001), indicating that this study
could reflect an association between genetic polymorphisms and
aspirin hypersensitivity in asthmatics. In subjects of 2nd stage, the
values of predicted FEV1 % and PC20 methacholine were
significantly lower in AIA patients than those of ATA controls,
whereas the total IgE level was higher in cases than in controls
(P,0.01). A significant decrease of body mass index (BMI) in
aspirin-intolerant asthmatics was also observed. In addition, the
mean age of first medical examination was significantly lower in
AIA than in the ATA group.
Genome-Wide Association Analyses
A total of 109,365 SNPs genotype assays were tested on the
DNA samples of 80 AIA and 100 ATA subjects using the
Illumina’s Human-1 Genotyping BeadChip. The overall call rate
of individual samples was over 98.0% after passing the genotype
quality threshold, and a total of 4,515 SNPs (4.1% of 109,365
SNPs) failed to provide accurate genotype results. In further
quality control analysis of the remaining 104,850 SNPs,
monomorphic, X-chromosomal and Hardy Weinberg Equilibri-
um-departed (P,0.001) SNPs were additionally omitted; the final
remaining 96,984 SNPs (88.7%) with an the average call rate of
99.9% were selected for analysis.
Table 1. Clinical profiles of aspirin-intolerant and aspirin-tolerant asthmatics.
Clinical profile First stage of genome-wide study Second stage of follow-up study
AIA ATA
Asthmatics
(all subjects) AIA ATA
AIA AIA-I
Number of subjects (n) 80 100 592 102 61 429
Age of onset [year, mean (range)] 45.06 (17.22–71.56) 45.56 (15.41–77.13) 46.15 (15.40–77.88) 42.76 (18.66–72.73) ** 43.73 (17.22–71.29) 47.30 (15.40–77.88)
Sex (n, male/female) 27/53 27/73 206/386 37/65 22/39 147/282
Current Smoker (%) 20.00 26.00 27.70 20.59 22.95 30.07
Height [cm, mean (range)] 161.8269.90 159.7568.45 160.7868.63 161.7069.91 161.7567.95 160.4268.39
Weight (kg) 61.74610.16 62.41610.32 62.81610.84 61.64610.39 60.61610.42 63.40610.97
Body mass index (kg/m2) 23.5763.20 24.4463.39 24.2463.39 23.5663.37** 23.0963.06** 24.5863.39
% decline of FEV1 by aspirin provocation 25.84614.00*** 0.9562.77 9.27613.24 33.59613.42*** 10.0766.74*** 3.5464.85
Blood eosinophil (%) 6.8765.79* 4.8964.16 6.0165.73 6.6565.78 4.8063.89 6.0365.92
FEV1 (% predicted) 82.53621.90 82.09620.69 90.54616.97 85.10616.41** 91.73617.12 91.66616.87
PC20 methacholine (mg/ml) 3.8866.80 2.8363.59 6.4368.67 4.2667.62** 6.2068.06 6.9168.90
Log[Total IgE (IU/ml)] 2.2160.52 2.1460.62 2.1660.63 2.2660.58 2.1560.45 2.1360.66
Positive rate of skin test (%) 58.75 63.00 56.42 48.04 60.66 57.81
Each clinical profile of AIA and AIA-I was compared to ATA controls, respectively.
*P,0.05;
**P,0.01;
***P,0.0001.
AIA, aspirin-intolerant asthma; AIA-I, intermediate aspirin-intolerant asthma; ATA, aspirin-tolerant asthma.
doi:10.1371/journal.pone.0013818.t001
GWAS of AIA
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co-dominant model, the 11 SNPs in the gene region that had the
most significant association signals were screened for the second
stage of follow-up study (Table 2).
Follow-up Study of Second Stage
For the follow-up study, the 11 genetic variants ‘‘within gene
regions’’ with the lowest P value (P,0.0001) for risk of aspirin
intolerance were selected. Then, 150 common SNPs in 11
candidate genes with minor allele frequency of over 0.05 based
on Asian population were selected from the International
HapMap Project (http://hapmap.ncbi.nlm.nih.gov/) and geno-
typed in 163 AIA subjects including AIA-I group, and 429 ATA
subjects. In order to include the maximum number of patients
with aspirin hypersensitivity, 80 AIA and 100 ATA subjects from
the first stage were included in the second stage due to the rareness
of the AIA condition. The case/control associations between
genotype and aspirin intolerance in asthmatics were analyzed
using multivariate logistic analyses adjusted for initial diagnosed
age, sex, smoking status, atopy, and BMI. Polymorphisms of the
CEP68 gene showed the most significant association with AIA
compared to ATA controls in co-dominant model (Table 3,
P=6.0610
25 to 4.0610
25). Furthermore, a nonsynonymous SNP
(rs7572857G.A) of CEP68 gene that replaces glycine with serine
revealed to have the lowest P value among seven SNPs of the gene
(OR =2.63; 95% CI =1.64–4.21; P=6.0610
25 for co-dominant
model). This rs7572857G.A was also statistically significant in the
dominant model (P=0.0005), but not in recessive model (Table
S1). In further association analysis excluding the GWAS subjects
in the second set, the statistically significant association still
remained although reduced significances were observed (Table
S2).
This study also observed modest associations of other genes with
AIA. In particular, the intronic rs4867084G.A of the PDZK3
gene (P=0.006 for co-dominant model) and rs11060333C.To f
the LRRC43 gene (P=0.009 for co-dominant model) showed
significant associations with AIA (Table S3). In addition, several
intergenic SNPs showed significant associations with AIA in our
GWAS results (P,0.0001; Table 4). Two SNPs, rs139719 and
rs7744030, were identified as intergenic SNPs during the first stage
of GWAS (build 126 of dbSNP database version), but they have
been recently listed as intronic SNPs (build 130 of dbSNP). On the
other hand, as for other nearby potential genes in the region where
CEP68 is located, the RAB1A gene, despite the lack of reports
showing direct relations with aspirin and/or respiratory disease,
was also found to be associated with AIA by composing a strong
LD with CEP68 (P,0.01; Figure 1).
Pair-wise comparisons among SNPs of CEP68 gene showed
tight LDs (Figure 2, Table S4). After haplotypes were inferred
using PHASE software, results from logistic analyses for
associations between haplotypes and aspirin intolerance showed
that haplotype CEP68_ht4 (T-G-A-A-A-C-G) of AIA was more
frequent than that of ATA as a control group, showing that the
CEP68_ht4 with the nonsynonymous rs7572857 ‘‘A’’ allele at the
fourth position was significantly associated with AIA in both the
co-dominant (OR =2.63; 95% CI =1.64–4.21; P=6.0610
25,
Table 3) and dominant models (OR =2.49; 95% CI =1.49–4.15;
P=0.0005; Table S1) when compared to that of ATA as a control
group.
Effect of rs7572857 on the Decline of FEV1 by Aspirin
Provocation
In regression analyses, the genotypes of several polymorphisms
in the CEP68 gene were also significantly associated with the
decline of FEV1 by aspirin provocation. Four SNPs, rs2302647,
rs2252867, rs2723087, and rs6741255, showed a similar distribu-
tion pattern with about two-fold increase in the mean decline of
FEV1 for the homozygous rare genotype compared to the
homozygous common genotype (Table 5). In the case of
rs7572857G.A, however, the nonsynonymous nucleotide substi-
tution showed a different distribution with about a four-fold
increase in the mean decline of FEV1 for the homozygote of the
rare allele (Figure 3), indicating that rs7572857 could have a
stronger influence on the higher decline of FEV1 by aspirin
provocation than other variants. Despite our findings on the
relationship between SNP genotypes and decline in FEV1 among
Table 2. Top 11 Genetic variants within gene regions with lowest P value for risk of aspirin intolerance.
SNP ID Gene Chr. locus Variation Position Function MAF P value*
AIA (n=80) ATA (n=100)
rs1053744 SBF1 22q13.33 C.T Exon39 SET binding factor 1 0.500 0.365 3.0610
27
rs828616 DCBLD2 3q12.1 A.G Exon 6 Discoidin, CUB and LCCL domain containing 2 0.195 0.365 2.0610
26
rs3213729 WDR21A 14q24.3 C.G Promoter DDB1 and CUL4 associated factor 4 0.230 0.100 1.0610
25
rs1932523 FILIP1 6q14.1 T.C Intron1 Filamin A interacting protein 1 0.465 0.290 3.0610
25
rs4867084 PDZK3 5p13.3 G.A Intron1 PDZ domain containing 2 0.200 0.365 4.0610
25
rs11060167 LRRC43 12q24.31 C.A Exon8 Leucine rich repeat containing 43 0.225 0.380 4.0610
25
rs6498124 CIITA 16p13.13 G.T Intron6 Class II, major histocompatibility complex,
transactivator
0.350 0.535 4.0610
25
rs2564978 DAF 1q32.2 T.C Promoter CD55 molecule, decay accelerating factor for
complement
0.535 0.390 5.0610
25
rs2295017 ENPP5 6p12.3 A.T3 9UTR Ectonucleotide pyrophosphatase/
phosphodiesterase 5
0.090 0.215 5.0610
25
rs2252867 CEP68 2p14 A.G Intron1 Centrosomal protein 68 kDa 0.415 0.250 7.0610
25
rs4245976 C6 5p13 C.T Intron6 Complement component 6 0.250 0.156 7.0610
25
MAF, minor allele frequency; Chr., chromosome.
*P values of co-dominant model. UTR; untranslated region.
doi:10.1371/journal.pone.0013818.t002
GWAS of AIA
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that rs7572857 has an effect on AIA (P=0.003; Table S5), but not
on ATA.
Discussion
To our knowledge, this is the first genome-wide association
study for AIA. Our results identified CEP68 as a positive risk factor
for the development of aspirin intolerance in asthmatics. Two
stages of genome-wide analysis and a follow-up study were used to
reduce the number of false-positive SNPs and retain statistical
power. In the present study, logistic and regression analyses
yielded significant associations between variations of the CEP68
gene and AIA, with the lowest P value at the nonsynonymous SNP
rs7572857. In addition, with a tight LD among the SNPs of the
CEP68 gene, the haplotype CEP68_ht4 (T-G-A-A-A-C-G) in AIA
subjects was more frequent when compared to that of ATA
controls and was significantly associated with AIA. In particular,
the fourth positioned ‘‘A’’ that was derived from rs7572857G.A
was found only in haplotype CEP68_ht4. On the other hand,
although we also do not rule out a possible protective effect of
rs10496123G.A due to its decreased risk for AIA (OR =0.81;
Table 3), it is considered that haplotype CEP68_ht4, which
includes most minor alleles of the significantly associated SNPs
and the major G allele of rs10496123G.A, may mainly affect the
association with AIA.
Although the inclusion of intermediate AIA in AIA case group
also showed significant associations with the SNPs and haplotypes
of CEP68 gene compared to ATA controls, a more correct
association for genetic polymorphisms and aspirin intolerance is
suggested to the comparison between AIA subjects without
intermediate AIA group and ATA controls (Table 3). On the
other hand, when observing the effects of polymorphisms of
CEP68 on the decline of FEV1 by aspirin provocation, the
homozygous AA of rs7572857G.A variant showed a different
distribution and a more significant increase of FEV1 decline in
Table 3. Logistic analyses of SNPs in the CEP68 gene between AIA and ATA.
Position
Amino acid
change AIA (n=102) vs. ATA (n=429) [AIA+AIA-I] (n=163) vs. ATA (n=429)
Frequency
a Co-dominant model Frequency
a Co-dominant model
AIA ATA OR (95% CI) P* P
corr** [AIA+AIA-I] ATA OR (95% CI) P* P
corr**
SNP
rs2302647 C.T Promoter 0.456 0.309 1.82 (1.32–2.50) 0.0002 0.001 0.399 0.309 1.46(1.12–1.91) 0.006 0.02
rs2252867 A.G Intron1 0.461 0.319 1.78 (1.30–2.45) 0.0004 0.002 0.414 0.319 1.50(1.15–1.96) 0.003 0.01
rs12611491 A.G Exon2 Arg27Gly 0.284 0.241 1.25 (0.88–1.79) 0.22 - 0.285 0.241 1.28(0.95–1.74) 0.1 -
rs7572857 G.A Exon2 Gly74Ser 0.176 0.077 2.63 (1.64–4.21) 6.0610
25 0.0003 0.126 0.077 1.71(1.11–2.62) 0.02 -
rs2723087 T.A Intron2 0.461 0.319 1.78 (1.30–2.45) 0.0004 0.002 0.414 0.319 1.50(1.15–1.96) 0.003 0.01
rs6741255 T.C Intron5 0.466 0.317 1.87 (1.35–2.57) 0.0001 0.0005 0.417 0.317 1.55(1.18–2.03) 0.002 0.007
rs10496123 G.A Intron5 0.289 0.339 0.81 (0.58–1.14) 0.23 - 0.304 0.339 0.85(0.64–1.13) 0.27 -
Haplotype
CEP68_ht1 0.240 0.340 0.60(0.42–0.86) 0.006 0.276 0.340 0.73(0.54–0.97) 0.03
CEP68_ht2 0.289 0.331 0.84(0.60–1.17) 0.3 0.304 0.331 0.88(0.66–1.17) 0.38
CEP68_ht3 0.275 0.218 1.34(0.93–1.93) 0.12 0.267 0.218 1.32(0.97–1.79) 0.08
CEP68_ht4 0.176 0.077 2.63(1.64–4.21) 6.0610
25 0.126 0.077 1.71(1.11–2.62) 0.02
aThe frequency of SNP indicates the minor allele frequency.
*P values represent the co-dominant model, which includes the additive model, adjusted for age at initial diagnosis, sex, smoking status, atopy, and body mass index.
**P
corr values after multiple testing correction.
AIA, aspirin-intolerant asthma; AIA-I, intermediate aspirin-intolerant asthma; ATA, aspirin-tolerant asthma; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0013818.t003
Table 4. Intergenic SNPs with lowest P value for risk of aspirin intolerance in the first stage of GWAS.
SNP ID Variation Build 126 Build 130 MAF P value*
Position Nearby Gene AIA (n=80) ATA (n=100)
rs139719 C.T Intergenic bA9F11.1 SGSM1 0.268 0.475 1.6610
26
rs7744030 C.T Intergenic ENPP4 CLIC5 0.081 0.245 1.1610
25
rs7963956 T.G Intergenic FAM19A2 0.311 0.151 4.0610
25
rs4501026 A.C Intergenic C21orf94 0.292 0.485 6.0610
25
rs346416 C.A Intergenic IPO11 0.268 0.440 7.3610
25
*P values of co-dominant model. Build 126 and 130 represent the versions of dbSNP.
MAF, minor allele frequency; AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma.
doi:10.1371/journal.pone.0013818.t004
GWAS of AIA
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were found to have the homozygote of this rare allele (AA), with
34.80% FEV1 decline; whereas no ATA controls were observed to
have the AA genotype (Table S5). This observation suggests that
the change from glycine to serine could have an effect on the
higher decline of FEV1 by aspirin provocation.
More recently, there have been debates concerning whether
GWAS can successfully detect the variants that are associated with
diseases. However, GWAS not only has made it possible to predict
risk factors that are associated with diseases, but also has
discovered additional variants that are associated with many
diseases [34,35]. Although dense genome-wide genotyping chips
containing over 600 K and as many as 1 M SNPs have been
recently developed, this study used the earlier chip with about
100 K SNPs due to the starting date of our research. Significantly,
ours is the first GWAS to identify genetic factors that might
influence the occurrence of aspirin intolerance in asthmatics. On
the other hand, while GWAS have found many common variants
that have modest effects on human common diseases, albeit some
may have a key role, whereas the systematic identification of rare
variants that are too rare to be detected in the GWAS and confer a
substantial risk of the diseases is also required [36]. In terms of our
Figure 1. Other potential candidate gene nearby CEP68. (A) Associations of other potential genes nearby CEP68. A significant association of
SNPs in RAB1A is found from the result of this GWAS (P,0.01). (B) LD Plot between CEP68 and RAB1A. LD coefficient (D’) among SNPs of SLC1A4,
RAB1A and CEP68 in Korean population.
doi:10.1371/journal.pone.0013818.g001
GWAS of AIA
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contained an insufficient sample size. Statistical powers of 72% in
the first GWAS stage and 52% after selecting 150 SNPs in the first
stage were estimated by QpowR, an interactive power calculator
for two stage association studies [37]. In addition, after Bonferroni
correction for multiple comparisons, only two SNPs, rs1053744 in
SBF1 and rs828616 in DCBLD2, were significantly associated with
AIA. However, this study applied a modest threshold (P,0.0001)
to select top 11 candidate genes because we focused on the SNPs
within a gene region. Moreover, the follow-up study for 11
promising candidate genes increased the power to calculate the
association between the CEP68 gene and aspirin intolerance in
asthmatics.
Since CEP68 gene (also referred to as KIAA0582) in the
chromosome 2p14 has been recently discovered, its functions have
not been fully understood, except for its role in centrosome
cohesion and epidermal growth factor (EGF) signaling [38,39]. In
addition, given that smoke is a risk factor for asthma, CEP68 has
been reported to be differentially expressed following exposure to
environmental smoke [40]. However, the functions of the CEP68
protein are not yet fully understood. Thus, our findings provide a
new insight into the relationship between CEP68 and aspirin
intolerance in asthma. In particular, it is suggested that the
Gly74Ser substitution in exon2 of the CEP68 gene could affect the
polarity of the protein structure (Figure 4A), or affect the function
of the CEP68 protein itself [41,42]. Although in silico annotation
showed that the nonsynonymous rs7572857G.A (Gly74Ser)
appeared to be tolerable to diseases, this site was not highly
conserved among mammals (Figure S1). Furthermore, in an
additional functional site prediction, it was found that amino acids
including 74Gly and its nearby positions could be targets for
several kinases (Figure 4B). Since SH domains are especially
unique sequences for several regulators, the change from glycine to
serine might play an important role in correlations with other
modulators. Therefore, phenotypic studies investigating the effects
of minor A allele of rs7572857 on protein activity of CEP68 in
relation to aspirin sensitivity are needed in the future.
Linkage disequilibrium, as a nonrandom association, has been
considered to be profoundly associated with recombination hot
spots, quantitative characters, and complex diseases [43]. In
addition, experimental evidence has shown an association between
haplotype blocks and hot spots of recombination [44]. When
compared with other populations from HapMap, the asthmatic
subjects in the Korean population showed a stronger LD from the
Figure 2. Physical Map, Haplotypes, and LD Plot of CEP68. (A) Physical map of CEP68 and its targeted SNPs. (B) Haplotypes of CEP68.
Associations of haplotypes with frequency .0.05 are shown in Table 3. (C) LD coefficient (D’) among CEP68 SNPs in a Korean population.
doi:10.1371/journal.pone.0013818.g002
GWAS of AIA
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was closest to that of the Chinese (Figure S2). Given the significant
association of haplotype CEP68_ht4 with AIA, the LD of CEP68
might facilitate mapping out genetic factors that function in aspirin
metabolism and/or aspirin hypersensitivity in asthma. Therefore,
further replications in AIA patients from other populations are
required to establish whether or not these structural variations
affect AIA.
Other previous reports have suggested associations between
genetic polymorphisms and AIA. In one study, 370 SNPs of 63
candidate genes that are involved in the arachidonic acid metabolic
cascade were studied for associations with AIA. The results
demonstrated that SNPs in the promoter region of the prostaglan-
din E2 receptor subtype 2 gene were significantly associated with
AIA [15]. Several SNPs in the promoter of LTC4S [19,45] and
ALOX5 [20] that encode key enzymes for CysLT synthesis also
showed significant associations with AIA [13,46]. In addition, three
promoter polymorphisms in the cysteinyl leukotriene receptor 1
gene were associated with AIA in males [46]. Moreover,
polymorphisms of genes that are involved in the pathways of
immune response and inflammation are also associated with aspirin
hypersensitivity in asthma [21,25]. This study also confirmed that
several other genes, which were associated previously with AIA,
showed significant association signals with AIA pathogenesis,
especially in the TNF, TGF, HLA-DPB1, ALOX5 and IL-10 genes
(Table S6). Despite the many studies that have shown positive
associations, a comprehensive association between genetic risks and
aspirin hypersensitivity has not yet been discovered. Furthermore,
constant revisions to find new risk alleles areneeded[35,47].Hence,
our findings on the first genome-wide and follow-up studies of AIA
couldbeabreakthroughinthe discoveryofsusceptiblegenesusinga
different approach.
In conclusion, this study confers a positive association between
CEP68 and aspirin-intolerant asthma, suggesting that these
findings would be useful for further genetic investigations of
NSAIDs metabolism as well as other inflammatory diseases.
However, this study does have several limitations. First, this study
included only the top 11 genes for the follow-up study due to
research budget constraints. Second, our second stage replication
analysis was insufficient due to the inclusion of samples from the
first stage. In addition, AIA-I patients who were also referred to as
positive responders to aspirin hypersensitivity [48,49] were
included in the second round. Although the significances were
reduced in the further association analysis without the GWAS
subjects due to the high proportion of AIA-I in the second round,
the statistically significant association of the SNPs including
nonsynonymous rs7572857G.A with AIA still remained (Table
S2). Therefore, further replication studies in a larger number of
subjects are also needed. Finally, functional studies of the
nonsynonymous SNP rs7572857 in the future could provide
important insights into the genetic etiology of aspirin intolerance
in asthmatics.
Figure 3. Effect of rs7572857G.Ai nCEP68 on the Decline of
FEV1 by Aspirin Provocation. Distribution presents the mean 6 SE
values of % decline of FEV1 by aspirin provocation in each genotype of
the nonsynonymous SNP (rs7572857G.A) in the CEP68 gene. The
homozygote of the rare allele (AA) showed a significant increase in
decline of FEV1.
doi:10.1371/journal.pone.0013818.g003
Table 5. Association between genotypes of the CEP68 gene and the decline of FEV1 by aspirin provocation.
SNP ID C/C C/R R/R P*
n Decline of FEV1 (%) n Decline of FEV1 (%) n Decline of FEV1 (%)
rs2302647 C.T 268 7.21611.22 255 10.00613.81 69 14.26616.36 5.0610
25
rs2252867 A.G 258 7.20611.39 261 9.95613.69 73 13.85616.03 9.0610
25
rs12611491 A.G 324 8.20612.35 233 10.79614.63 33 8.92610.11 0.09
rs7572857 G.A 492 8.39612.34 95 12.26615.85 5 34.80610.76 3.0610
25
rs2723087 T.A 258 7.20611.39 261 9.95613.69 73 13.85616.03 9.0610
25
rs6741255 T.C 256 7.20611.42 266 9.84613.60 70 14.36616.16 5.0610
25
rs10496123 G.A 264 10.34614.28 265 8.55612.32 63 7.46612.01 0.06
*P values of regression analyses represent the co-dominant model adjusted for age at initial diagnosis, sex, smoking status and atopy.
C/C, C/R and R/R indicate the homozygote of the common allele, and the heterozygote and homozygote of the rare allele, respectively.
Decline of FEV1 represents mean 6 SE value.
doi:10.1371/journal.pone.0013818.t005
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Study Subjects
The subjects were recruited from Soonchunhyang University,
Chung Ang University, Chung Nam University, Chungbuk
University, and Seoul National University in Korea in a span of
about 6 years (between 2003 and 2008). All subjects were Korean.
All patients were diagnosed by a physician and met the definition
of asthma set forth in the Global Initiative for Asthma guidelines
[50]. All patients had a history of dyspnea and wheezing during
the previous 12 months, plus one of the following: (1) .15%
increase in FEV1 or .12% increase plus 200 mL following
inhalation of a short-acting bronchodilator, (2) ,10 mg/mL PC20
methacholine, and (3) .20% increase in FEV1 following 2 weeks
of treatment with inhaled steroids and long-acting bronchodila-
tors. Twenty-four common inhalant allergens were used for a skin
prick test [26]. Atopy was defined as having a wheal reaction over
3 mm in diameter. Total IgE was measured by the CAP system
(Pharmacia Diagnostics, Uppsala, Sweden). The asthmatic
patients had experienced no exacerbation of asthma and
respiratory tract infection in the 6 weeks preceding the oral
aspirin challenge (OAC). The OAC was performed with
increasing doses of aspirin using methods slightly modified from
those described previously [26,49]. Changes in FEV1 were
followed for 5 hours after the last aspirin challenge dose.
Aspirin-induced bronchospasms, as reflected by rate (%) of
FEV1 decline, were calculated as the pre-challenge FEV1 minus
the post-challenge FEV1 divided by the pre-challenge FEV1. OAC
reactions were categorized into three groups as follows: Subjects
with 20% or greater decreases in FEV1 or 15% to 19% decreases
in FEV1 with naso-ocular or cutaneous reactions were designated
as the AIA group, those with 15% to 19% decreases in FEV1 or
naso-ocular or cutaneous reactions only were the AIA-I group,
and those with less than 15% decreases in FEV1 without naso-
ocular or cutaneous reactions were the ATA group. The
distribution of FEV1 decline rate of subjects is shown in Figure
Figure 4. Helical Wheel Projection and Properties between 74Gly and 74Ser, and Motif Search. The helical wheel projection of Gly74Ser
is presented by the Expert Protein Analysis System (ExPASy). The change from 74Gly (A) to 74Ser (B) showed an increase in polarity due to its
interactions with nearby polar amino acids. The solid surface energy and the degree of vapor/H2O distribution of glycine and serine were compared.
(C) Motifs including 74Gly and nearby 74Gly for the functional site were found using a prediction program (http://elm.eu.org/index.html).
doi:10.1371/journal.pone.0013818.g004
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approved by the Institutional Review Board of each hospital.
The First Stage of Genome-Wide SNP Genotyping
About 750 ng of genomic DNA from 80 AIA cases and 100
ATA controls was used to genotype each sample on the Illumina’s
Human-1 Genotyping BeadChip (Illumina, San Diego, USA).
Genotyping was performed according to Illumina’s assay manual.
Briefly, each sample was processed by whole-genome amplifica-
tion, fragmentation, precipitation, and resuspension in an
appropriate hybridization buffer. Denatured samples were hy-
bridized on the prepared Human-1 Genotyping BeadChip for
16 h at 48uC. Then, the processed beadchip for the single-base
extension reaction was stained and imaged on an Illumina Bead
Array Reader. To convert fluorescent intensities into SNP
genotypes, normalized bead intensity data obtained for each
sample were loaded into the Beadstudio 3.0H software (Illumina).
SNP clusters for genotype calling of all SNPs were examined using
Beadstudio 3.0H software. The overall call rate for all SNPs was
98.0%.
The Second Stage of Follow-up Study
Eleven genes that include the GWAS-driven top SNPs, which
are positioned not at intergenic region but at the 59-untranslated
region (UTR), exons, introns, and the 39-UTR region, were
selected for the follow-up study. For the next study, a total of 150
common SNPs within 11 candidate genes, including nearby
upstream region (1.5 kb) of each gene, (8 SNPs for the SBF1 gene;
12 for DCBLD2; 15 for WDR21A; 34 for FILIP1; 2 for PDZK3;1 5
for LRRC43; 18 for CIITA; 5 for DAF; 7 for ENPP5; 7 for CEP68;
27 for C6, respectively) were genotyped using a total of 163 AIA
cases including AIA-I subjects and 429 ATA controls. The SNPs
were scanned using BeadExpressH (Illumina, San Diego, USA).
Statistics
For genome-wide analysis, associations of genotype distributions
between AIA cases and ATA controls were calculated by logistic
analyses. In addition to the genetic homogeneity of the study
subjects as described above, a parameter (l) of genomic control
was calculated in this study by dividing median x
2 statistics by
0.456, with an estimate of 1.056 [51]. Power calculations of the
first GWAS stage and after selecting candidate SNPs in the first
stage were estimated using QpowR program (https://www.msu.
edu/ ˜steibelj/JP_files/QpowR.pdf). In the association analysis of
the polymorphisms in CEP68, we examined Lewontin’s D’ (|D’|)
and the LD coefficient r
2 between all pairs of biallelic loci [52].
Haploview v4.1 software downloaded from the Broad Institute
(http://www.broadinstitute.org/mpg/haploview) was used to
determine LD of CEP68 [53]. Haplotypes were first estimated
using the PHASE software [54], and then computed by logistic
analyses using the Statistical Analysis System (SAS) program.
Subjects harboring missing genotypes were omitted in the analysis
of individual SNPs and haplotypes. Comparisons of genotype
distributions between AIA and ATA were carried out with logistic
analyses adjusted for initial diagnosed age, sex, smoking status,
atopy, and body mass index as multivariates using SAS. The
common (C) alleles were used as the referent genotype to the
heterozygote and homozygote of the rare (R) allele. The effective
numbers of independent marker loci in each gene were calculated
to correct for multiple testing using the software SNPSpD (http://
genepi.qimr.edu.au/general/daleN/SNPSpD/), which is based on
the spectral decomposition (SpD) of matrices of pair-wise LD
between SNPs. Significant associations were represented by P
value ,0.05.
Supporting Information
Table S1 Comparison of co-dominant, dominant and recessive
models for SNPs in the CEP68 gene between AIA and ATA.
Found at: doi:10.1371/journal.pone.0013818.s001 (0.07 MB
DOC)
Table S2 Association analysis without GWAS samples in the
second replication round analysis.
Found at: doi:10.1371/journal.pone.0013818.s002 (0.05 MB
DOC)
Table S3 Logistic analyses of 150 SNPs in Top 11 genes
between AIA and ATA.
Found at: doi:10.1371/journal.pone.0013818.s003 (0.34 MB
DOC)
Table S4 LD coefficients (D’ and r2) among CEP68 polymor-
phisms.
Found at: doi:10.1371/journal.pone.0013818.s004 (0.03 MB
DOC)
Table S5 Relation of the SNP genotypes in CEP68 to the
decline on FEV1 in AIA and in ATA.
Found at: doi:10.1371/journal.pone.0013818.s005 (0.05 MB
DOC)
Table S6 List of other genes that were associated previously with
AIA.
Found at: doi:10.1371/journal.pone.0013818.s006 (0.05 MB
DOC)
Figure S1 In silico annotation of nonsynonymous rs7572857G.A
(Gly74Ser). Impact on protein function and conservation across
species are predicted by the SNPs3D program (http://www.snps3d.
org/). (A) The higher scores of entropy and Position Specific Scoring
Matrix (PSSM) indicate more tolerable to diseases. (B) The 74th
amino acid of CEP68 is not highly conserved among mammals.
Found at: doi:10.1371/journal.pone.0013818.s007 (0.17 MB
DOC)
Figure S2 Comparison of LD from other populations for the
selected CEP68 SNPs. The LDs are constructed by seven CEP68
SNPs that are equivalent with this study from HapMap (http://
hapmap.ncbi.nlm.nih.gov/index.html.en). CEU, Caucasian;
CHB, Chinese, JPT, Japanese; YRI, African.
Found at: doi:10.1371/journal.pone.0013818.s008 (0.12 MB
DOC)
Figure S3 Distribution of FEV1 decline rate. Distributions are
calculated from the decline rate of FEV1 by aspirin provocation
and its number of subjects with 5% intervals. The distribution of
AIA patients with FEV1 decline rate less than 15% is due to the
responders to naso-ocular or cutaneous reactions.
Found at: doi:10.1371/journal.pone.0013818.s009 (0.03 MB
DOC)
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